Purification of clavulanic acid produced by Streptomyces clavuligerus via submerged fermentation using polyethylene glycol/cholinium chloride aqueous two-phase systems

Panas, Paweł; Lopes, Camila Soares; Cerri, Marcel O.; Ventura, Sónia P. M.; Santos-Ebinuma, Valéria de Carvalho; Pereira, Jorge Fernando Brandão

doi:10.1016/j.fluid.2017.07.005

Cited by 17 publications

(12 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Panas et al [ 132 ], who attempted the purification of CA produced by S. clavuligerus via submerged fermentation using different ATPS, obtained the highest CA recovery yield (64.91%) and purification factor (22.70) with PEG-600/sodium polyacrylate-8000 and PEG-600/cholinium chloride, respectively. These results support the use of these systems as effective techniques to purify CA from fermented broth in a single partitioning step.…”

Section: Production Of β-Lactamase Inhibitorsmentioning

confidence: 99%

“…Mycobacteria antibiotic resistance is multifactorial, including enzyme inactivation and cell wall impenetrability [ 133 ]. Additionally, because this bacteria group developed genetic and epigenetic resistance through selection [ 132 ], treatment options for mycobacteria have been restricted and inert for over thirty years [ 134 ]. An example is the rapid and global diffusion of genes of strains with multidrug resistance such as NDM-1-producing K. pneumoniae [ 135 ].…”

Section: β-Lactamase Inhibitors In Clinical Practicementioning

confidence: 99%

See 1 more Smart Citation

Production of β-Lactamase Inhibitors by Streptomyces Species

et al. 2018

View full text Add to dashboard Cite

β-Lactamase inhibitors have emerged as an effective alternative to reduce the effects of resistance against β-lactam antibiotics. The Streptomyces genus is known for being an exceptional natural source of antimicrobials and β-lactamase inhibitors such as clavulanic acid, which is largely applied in clinical practice. To protect against the increasing prevalence of multidrug-resistant bacterial strains, new antibiotics and β-lactamase inhibitors need to be discovered and developed. This review will cover an update about the main β-lactamase inhibitors producers belonging to the Streptomyces genus; advanced methods, such as genetic and metabolic engineering, to enhance inhibitor production compared with wild-type strains; and fermentation and purification processes. Moreover, clinical practice and commercial issues are discussed. The commitment of companies and governments to develop innovative strategies and methods to improve the access to new, efficient, and potentially cost-effective microbial products to combat the antimicrobial resistance is also highlighted.

show abstract

Section: Production Of β-Lactamase Inhibitorsmentioning

confidence: 99%

Section: β-Lactamase Inhibitors In Clinical Practicementioning

confidence: 99%

Production of β-Lactamase Inhibitors by Streptomyces Species

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Organicc hemists and chemicali ndustries are lastly embracing biocatalysis as ak ey enabling technology to access more complex synthetic schemes in am ore sustainable manner. [1,2] However,t he use of enzymes as isolated soluble catalysts suffers the limitations of the homogeneous catalysis where product purification is arduous and the catalysts are hardly reused. [3] Furthermore, the enzymes have been majorly evolved to work under mild conditions (room temperature, neutral pH, atmospheric pressure) within the crowded environment of the cell milieu, thus their stabilityb ecomes an issue when the chemical process demands harsh and diluted reactionc onditions.…”

Section: Introductionmentioning

confidence: 99%

Single‐Particle Studies to Advance the Characterization of Heterogeneous Biocatalysts

et al. 2018

View full text Add to dashboard Cite

Immobilized enzymes have been widely exploited because they work as heterogeneous biocatalysts, allowing their recovery and reutilization and easing the downstream processing once the chemical reactions are completed. Unfortunately, we suffer a lack of analytical methods to characterize those heterogeneous biocatalysts at microscopic and molecular levels with spatio‐temporal resolution, which limits their design and optimization. Single‐particle studies are vital to optimize the performance of immobilized enzymes in micro/nanoscopic environments. In this Concept article, we review different analytical techniques that address single‐particle studies to image the spatial distribution of the enzymes across the solid surfaces, the sub‐particle substrate diffusion, the structural integrity and mobility of the immobilized enzymes inside the solid particles, and the pH and O2 internal gradients. From our view, such sub‐particle information elicited from single‐particle analysis is paramount for the design and fabrication of optimal heterogeneous biocatalyst.

show abstract

“…From E. coli fermented broth or cell lysate, the extraction of proteins, virus, plasmid DNA (pDNA) and enzymes has been reported . ABS‐based protocols can also be applied to recover toxin A and enzymes, from Clostridium perfringens , virus from Salmonella typhimurium, pigments from Spirulina platensis, enzymes from Penicillium restrictum, Penicillium janthinellum , and Bacillus sp, antibiotics from Streptomyces aureofaciens and pharmaceuticals from Streptomyces clavuligerus , . Yeast is also popular for biomolecules synthesis, and there are ABS studies showing the recovery of enzymes from S. cerevisiae and proteins from P. pastoris and bakers' yeast …”

Section: Introductionmentioning

confidence: 99%

“…Thus, in the last decade, several ABS combining ILs and polymers, salts, alcohols, among others as phase‐forming agents, have been determined and proposed as alternative separation processes , , , . Their use as effective extractive platforms were also demonstrated to recover several bioproducts from fermented broth, such as antibiotics (penicillin G, tetracycline, clavulanic acid), lipase,, , polysaccharides and colorants/pigments . In Table , a summary of IL‐based ABS already applied for the extraction of bioproducts from fermented broth is depicted, in which is provided some details regarding the producer microorganism, the type of IL‐based system (ILs and co‐existing phase forming agents used) and partitioning/purification yields.…”

Section: Introductionmentioning

confidence: 99%

Liquid–liquid extraction of biopharmaceuticals from fermented broth: trends and future prospects

Santos

Santos-Ebinuma

Pessoa

et al. 2017

J of Chemical Tech & Biotech

Self Cite

View full text Add to dashboard Cite

Biopharmaceuticals are one of the most important groups of biotechnological products, representing one-quarter of all pharmaceutical sales and providing suitable and efficient medical care for many previously untreatable diseases. However, their production and purification usually require complex processes, resulting in extremely expensive final products. Thus, the development of newer, simpler and cheaper methods for biosynthesis and purification of these biocompounds, as well as proper integration between these stages, are crucial to reduce their commercial costs and to increase the scale of biopharmaceuticals' medical use. One solution for this concern relies on the proper integration between upstream and downstream processing applying liquid-liquid extraction systems as an intermediate stage. Recently, several works reported that a proper choice of liquid-liquid systems such as aqueous biphasic systems (ABS) can be a suitable platform to simplify, reduce the number of the downstream stages, improve the recovery and purification yields and, consequently, decrease biopharmaceuticals' manufacturing costs. This review will explain the general concept of biopharmaceuticals, their main production and purification methods, particularly, exploring the use of ABS as effective and integrative platforms for their recovery and purification, and providing further insights into the future trends and prospects in the field.

show abstract

Purification of clavulanic acid produced by Streptomyces clavuligerus via submerged fermentation using polyethylene glycol/cholinium chloride aqueous two-phase systems

Cited by 17 publications

References 55 publications

Production of β-Lactamase Inhibitors by Streptomyces Species

Production of β-Lactamase Inhibitors by Streptomyces Species

Single‐Particle Studies to Advance the Characterization of Heterogeneous Biocatalysts

Liquid–liquid extraction of biopharmaceuticals from fermented broth: trends and future prospects

Contact Info

Product

Resources

About